Citius Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended March 31, 2024. The filing was signed May 14, 2024. The company is a development-stage biopharmaceutical business and has not generated operating revenue.
Financial results and liquidity
| Metric | Three months ended March 31, 2024 | Six months ended March 31, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $3.61 million | $6.23 million |
| General and administrative expense | $4.29 million | $7.95 million |
| Stock-based compensation | $3.08 million | $6.14 million |
| Operating loss | $10.97 million | $20.31 million |
| Net loss | $8.54 million | $17.78 million |
| Basic and diluted loss per share | $0.05 | $0.11 |
| Net cash used in operating activities | Not provided for the quarter | $13.92 million |
At March 31, 2024, cash and cash equivalents were $12.56 million, working capital was approximately $17.4 million, and total assets were $90.71 million. Total liabilities were $10.74 million; the filing reports lease liabilities and a deferred tax liability, but no borrowings. The company reported no off-balance-sheet arrangements. Gross margin is not meaningful because there was no revenue.
Changes versus prior comparable periods
- Quarterly net loss narrowed by $1.98 million year over year, mainly from lower R&D and G&A expenses and a $2.39 million gain on sale of New Jersey tax losses; higher stock-based compensation partly offset these improvements.
- For the six-month period, net loss widened by $3.66 million year over year. Stock-based compensation increased $3.77 million, primarily due to the Citius Oncology stock plan.
- Six-month R&D expense declined $1.94 million, while G&A expense increased $0.55 million. Interest income fell to $0.44 million from $0.52 million.
- Cash declined from $26.48 million at September 30, 2023 to $12.56 million at March 31, 2024. Operating cash use increased to $13.92 million from $12.68 million in the prior-year six-month period.
Outlook, developments, and risks
- Liquidity and going concern: Management estimates cash resources, including proceeds from an April 30, 2024 capital raise, will fund operations through December 2024. The filing states that substantial doubt remains about the company’s ability to continue as a going concern within one year after issuance. Additional capital will be needed, and financing, partnerships, regulatory approval, and product revenue are not assured.
- April financing: A registered direct offering of 21,428,574 common shares and warrants to purchase the same number of shares was priced at $0.70 per share and accompanying warrant. Gross proceeds were $15 million and net proceeds approximately $13.8 million. Warrants have a $0.75 exercise price and five-year term, with exercise available after six months. As of May 10, 2024, 180,673,355 common shares were issued and outstanding.
- LYMPHIR: The FDA accepted the BLA resubmission on March 18, 2024, with an August 13, 2024 PDUFA goal date. The prior complete response letter required enhanced product testing and additional controls; the company says no additional clinical efficacy or safety trials were requested. The filing provides no assurance of approval.
- Mino-Lok: Enrollment in the pivotal Phase 3 trial was completed; 241 patients were enrolled and 109 catheter-failure events observed, above the minimum 92 required. The filing describes study close-out work but does not report trial results.
- Halo-Lido: Management anticipated an FDA end-of-Phase-2 meeting in the second quarter of calendar 2024 and planned to analyze Phase 2b data and plan a Phase 3 trial. Management expected R&D expenses to stabilize at current levels in fiscal 2024.
- Proposed Citius Oncology transaction: The merger with TenX was expected to close in the third quarter of 2024, subject to approvals and other conditions. Citius Pharma would receive 67.5 million shares of the combined company and contribute $10 million in cash. Completion and timing are not assured.
- Nasdaq listing: Nasdaq extended the deadline to regain the $1.00 minimum bid-price requirement to September 9, 2024. Failure to regain compliance could result in delisting proceedings.
- Potential dilution and contractual costs: At March 31, 2024, 50.7 million warrants and 17.1 million Citius Pharma plan options were outstanding; 7.6 million plan shares remained available for grants. Product licenses also carry potential milestone, royalty, and sublicense-payment obligations.
No formal revenue or earnings guidance is provided. Management’s stated operating priorities include LYMPHIR commercialization preparation, completing Mino-Lok trial activities, and planning Halo-Lido’s next development stage.
Important facts for investors to verify
- Whether LYMPHIR receives FDA approval by the August 13, 2024 goal date, and the timing and cost of any required launch.
- Whether Mino-Lok trial data support the program’s next regulatory steps; results are not provided in this filing.
- Cash use, financing needs, and the feasibility of funding operations beyond December 2024.
- Closing conditions and final terms of the proposed Citius Oncology business combination, including the $10 million contribution.
- Progress toward Nasdaq’s September 9, 2024 bid-price deadline and the effects of outstanding and newly issued warrants and shares on dilution.